首页> 外文期刊>Biologicals: Journal of the International Association of Biological Standardization >Protection of mice against gastric colonization of Helicobacter pylori by therapeutic immunization with systemic whole cell inactivated vaccines
【24h】

Protection of mice against gastric colonization of Helicobacter pylori by therapeutic immunization with systemic whole cell inactivated vaccines

机译:通过治疗免疫与系统性全细胞灭活疫苗治疗幽门螺杆菌胃定植的小鼠

获取原文
获取原文并翻译 | 示例
           

摘要

The protective effect of therapeutic immunization with heat inactivated Helicobacter pylori cells administered with aluminum phosphate as an adjuvant was evaluated with "Swiss albino mice" infected with H. pylori Sydney strain 1 (SS1). The presence of bacteria in histological sections of the stomach was evaluated to confirm the colonization of H. pylori. The infection dose was determined to be 1 x 10(8) cells which resulted to be the optimal concentration to sustain infection for required time. Systemic immunization of H. pylori 26695 and SS1 Whole cell heat inactivated vaccine were induced on mice. The IgG titer levels of high dose adjuvant vaccine of both strains were proportionate on the 7th and 14th day. Subsequently on the 21st and 28th day SS1 high dose adjuvant revealed a higher titer value. The Probability values were <0.0001 which is statistically significant. Moreover, therapeutic immunization with SS1 (WC) vaccine confers efficacious protection against H. pylori infection in mice. These results represent strong evidence for feasibility of therapeutic use of whole cell based vaccine formulations against H. pylori infection in animal model. (C) 2016 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.
机译:用H. pylori Xydney菌株1(SS1)感染的“瑞士白化小鼠”评价磷酸铝作为佐剂施用作为佐剂的磷酸铝的热灭活幽门螺杆菌细胞的保护作用。评价细菌在胃的组织学部分中的存在以确认H. Pylori的定植。测定感染剂量为1×10(8)个细胞,导致需要最佳浓度以维持所需时间的感染。在小鼠上诱导幽门螺杆菌26695和SS1全细胞热灭活疫苗的全身免疫。两种菌株的高剂量佐剂疫苗的IgG滴度水平在第7天和第14天比例。随后在第21天和第28天SS1高剂量佐剂揭示了更高的滴度值。概率值<0.0001,其统计学上显着。此外,用SS1(WC)疫苗的治疗性免疫赋予小鼠幽门螺杆菌感染的有效保护。这些结果代表了在动物模型中对幽门螺杆菌感染的整个细胞基疫苗配方的治疗用途可行性的有力证据。 (c)2016年生物标准化国际联盟。 elsevier有限公司出版。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号